特兰克萨姆酸与中度或重度创伤性脑损伤中发作之间的关联
David V Deshpande1, W Ian McKinley2, Andrew J Benjamin3
1Pritzker School of Medicine, University of Chicago, Chicago, Illinois.
The Journal of surgical research
|July 18, 2024
概括
在创伤性脑损伤 (TBI) 患者中,服用2g的前医院玻尿酸 (TXA) 并没有在72小时内增加发作风险. 需要进一步的研究来证实这些研究结果在TBI患者.
科学领域:
- 神经科学是一个神经科学.
- 创伤护理 创伤护理
- 药理学 药理学是指药理学的学科.
背景情况:
- 特兰胺酸 (TXA) 用于创伤性脑损伤 (TBI) 降低死亡率,特别是在内出血的情况下.
- 已知TXA可以以剂量依赖的方式降低发作值.
- 对于TBI患者的发作活动,医院前TXA的安全性需要进一步调查.
研究的目的:
- 在中度至重度TBI患者中,评估TXA2g医院前玻尿酸和72小时内活动之间的关联.
- 为了确定TXA的剂量是否影响TBI后发作的发生率.
主要方法:
- 对TBI临床试验的医院前TXA患者进行了二次分析.
- 包括格拉斯哥昏迷尺度<13和头部伤的患者.
- 对相关临床因素进行多变量逻辑回归控制,以评估TXA治疗组与发作发生率之间的关系.
主要成果:
- 在786名患者中,19名患者在72小时内发作.
- 与安慰剂 (OR 0.41,P=0.12) 相比,2g TXA玻尿酸组没有显著增加发作.
- 家庭抗发作药物的使用与发作发病率的增加密切相关 (OR 15.95,P<0.001).
结论:
- 在中度或重度的TBI中,医院前2g的TXA玻尿酸与在72小时内发作风险的增加无关.
- 局限性包括研究功率有限,持续电脑摄影的使用最小,以及缺乏预防数据.
- 需要进行进一步的研究,以最终确定TBI中医院前TXA的关于活动的安全概况.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
279
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
279
Antiepileptic Drugs: Glutamate Antagonists
311
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
311
Electroconvulsive Therapy
30
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
30
Antiepileptic Drugs: Potassium Channel Activators
162
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
162
Arteries of the Lower Limbs
182
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
182
Antiepileptic Drugs: Calcium Channel Blockers
359
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
359


